Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. [Review] (Record no. 2483)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02405nam a22003017a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 170710s20172017 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2168-8184 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| PMID | 28680788 |
| 245 ## - TITLE STATEMENT | |
| Title | Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. [Review] |
| 251 ## - Source | |
| Source | Cureus. 9(5):e1300, 2017 May 31 |
| 252 ## - Abbreviated Source | |
| Abbreviated source | Cureus. 9(5):e1300, 2017 May 31 |
| 253 ## - Journal Name | |
| Journal name | Cureus |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Year | 2017 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Manufacturer | FY2017 |
| 266 ## - Date added to catalog | |
| Date added to catalog | 2017-07-10 |
| 520 ## - SUMMARY, ETC. | |
| Abstract | Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis. This paper reviews the profile and potential of abaloparatide in the treatment of postmenopausal osteoporosis. This paper is based on clinical trials and a PubMed search. Search terms used were "abaloparatide", "BA058", and "PTHrP". This review outlines the effects of this anabolic PTHR1 activator, which increases bone mineral density in patients at high risk for osteoporosis. The potential adverse effects of abaloparatide are also summarized. Abaloparatide has 41% homology to parathyroid hormone (PTH) (1-34) and 76% homology to parathyroid hormone-related protein (PTHrP) (1-34). The molecule was meticulously selected to retain stability and potent bone anabolic activity, and it has a limited effect on bone resorption (hence, a low calcium-mobilizing potential). Abaloparatide has shown promising results in a reduction of new onset vertebral (approximately 86% reduction) and nonvertebral fractures (approximately 43% reduction). In clinical trials to date, abaloparatide appears to have a good safety and tolerability profile with a significantly lower degree of hypercalcemia compared to that of teriparatide. Based on the clinical trials, the optimum dose of abaloparatide is 80 mcg subcutaneous once daily. |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | PubMed-not-MEDLINE -- Not indexed |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
| Institution | MedStar Washington Hospital Center |
| 656 ## - INDEX TERM--OCCUPATION | |
| Department | Medicine/Internal Medcine |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Journal Article |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Local Authors | Kommalapati, Anuhya |
| 790 ## - Authors | |
| All authors | Correa R, Kommalapati A, Tella SH |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| DOI | <a href="https://dx.doi.org/10.7759/cureus.1300">https://dx.doi.org/10.7759/cureus.1300</a> |
| Public note | https://dx.doi.org/10.7759/cureus.1300 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Journal Article |
| Item type description | Article |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedStar Authors Catalog | MedStar Authors Catalog | 07/10/2017 | 28680788 | 28680788 | 07/10/2017 | 07/10/2017 | Journal Article |